サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1539765

ペプチドベースの代謝疾患治療薬の世界市場レポート 2024年

Peptide Based Metabolic Disorders Therapeutics Global Market Report 2024
出版日: | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.67円
ペプチドベースの代謝疾患治療薬の世界市場レポート 2024年
出版日: 2024年08月21日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ペプチドベースの代謝疾患治療薬市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR14.9％で521億6,000万米ドルに成長します。予測期間の成長は、新規ペプチドアナログの開発、代謝性疾患に対する研究開発投資の増加、精密医療アプローチの採用、新興国市場の拡大、医薬品開発における共同研究や提携、デリバリー技術の進歩、患者中心の治療への注力など、いくつかの主要な要因によるものと考えられます。予測期間中に予想される主な動向には、創薬における人工知能の応用、個別化治療の拡大、遺伝子治療におけるCRISPR/Cas9の活用、患者モニタリングのためのウェアラブルデバイスの統合、経口ペプチド製剤の開発、疾病管理におけるデジタル治療法の出現、個別化治療のためのバイオバンクの拡大などがあります。これらの動向は、今後数年間で、ペプチドベースの代謝疾患治療薬市場を大きく形成し、推進すると予想されます。

肥満の有病率の増加は、ペプチドベースの代謝疾患治療薬市場の成長を当面牽引すると予想されます。肥満は、体脂肪の過剰な蓄積とそれに伴う健康リスクを特徴とし、座りがちなライフスタイル、不健康な食事、遺伝的素因、カロリーの高い食品や運動不足を促進する環境の影響などの要因により、より一般的になりつつあります。代謝異常に対するペプチドベースの治療は、ペプチドを利用して代謝機能を調節し、インスリン感受性を改善し、食欲をコントロールすることにより、肥満などの病態を管理し、それによって患者の転帰を向上させ、これらの慢性疾患に伴う長期的な健康合併症を軽減することを目的としています。例えば、英国のOffice for Health Improvement and Disparitiesが2023年5月に発表した報告書によると、2021年から2022年にかけて、イングランドの18歳以上の成人の63.8％が過体重または肥満であると推定され、前年の63.3％からわずかに増加しました。したがって、肥満の有病率の増加は、ペプチドベースの代謝障害治療薬市場の主要な促進要因となっています。

ペプチドベースの代謝疾患治療薬市場の大企業は、アンメット・メディカル・ニーズに対応し、患者の治療選択肢を広げるため、ペプチド系抗糖尿病薬のバイオシミラーなど、革新的な治療薬の開発に注力しています。ペプチドベースの抗糖尿病薬バイオシミラーは、既存の糖尿病ペプチド治療薬を複製したもので、同様の有効性と安全性プロファイルを、競合価格戦略により潜在的な低コストで提供します。例えば、インドに本社を置くグレンマーク・ファーマシューティカルズ社は2024年1月、GLP-1受容体作動薬に属する一般的な抗糖尿病薬リラグルチドのバイオシミラーであるリラフィットを発売しました。これらの薬剤は、血糖値の調整に重要な天然のGLP-1ホルモンの作用を模倣します。臨床試験において、リラフィットは血糖コントロールの改善、体重減少の促進、心血管安全性の向上に有効であることが実証されており、これらは糖尿病、肥満、および関連する心血管疾患の管理において重要な利点です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界のペプチドベースの代謝疾患治療薬市場：促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のペプチドベースの代謝疾患治療薬市場の実績：規模と成長, 2018-2023
  • 世界のペプチドベースの代謝疾患治療薬市場の予測：規模と成長, 2023-2028, 2033年

第6章 市場セグメンテーション

  • 世界のペプチドベースの代謝疾患治療薬市場薬の種類別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • リラグルチド
  • エキセナチド
  • その他の薬剤の種類
  • 世界のペプチドベースの代謝疾患治療薬市場：用途別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • リソソーム蓄積症
  • 糖尿病
  • 肥満
  • 高コレステロール血症
  • その他の用途
  • 世界のペプチドベースの代謝疾患治療薬市場：流通チャネル別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域別・国別分析

  • 世界のペプチドベースの代謝疾患治療薬市場：地域別、実績と予測, 2018-2023, 2023-2028年, 2033年
  • 世界のペプチドベースの代謝疾患治療薬市場：国別、実績と予測, 2018-2023, 2023-2028年, 2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ペプチドベースの代謝疾患治療薬市場：競合情勢
  • ペプチドベースの代謝疾患治療薬市場：企業プロファイル
    • Pfizer Inc.
    • Johnson And Johnson
    • Roche Holding AG
    • Merck And Co. Inc.
    • AbbVie Inc.

第31章 その他の大手企業と革新的企業

  • Sanofi SA
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly Company
  • Amgen Inc.
  • Gilead Sciences Inc.
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Biogen Inc.
  • Vertex Pharmaceuticals Incorporated

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

目次
Product Code: r19203

Peptide-based therapeutics for metabolic disorders are pharmaceutical treatments derived from short chains of amino acids, known as peptides. These therapies target and modulate biological pathways involved in conditions such as diabetes, obesity, and related disorders. Their primary objectives include regulating hormone levels, improving insulin sensitivity, managing appetite, and controlling glucose metabolism, all aimed at enhancing patient outcomes and quality of life.

Key drugs in the peptide-based treatment of metabolic disorders include liraglutide, exenatide, and others. Liraglutide belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the action of natural GLP-1. This hormone regulates blood sugar levels by stimulating insulin release and inhibiting glucagon secretion. Liraglutide is utilized in the treatment of conditions such as lysosomal storage diseases, diabetes, obesity, hypercholesterolemia, among others. Distribution channels for these therapies include hospital pharmacies, retail pharmacies, and online pharmacies.

The peptide based metabolic disorders therapeutics market research report is one of a series of new reports from the business research company that provides peptide based metabolic disorders therapeutics market statistics, including peptide based metabolic disorders therapeutics industry global market size, regional shares, competitors with an peptide based metabolic disorders therapeutics market share, detailed peptide based metabolic disorders therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide based metabolic disorders therapeutics industry. This peptide based metabolic disorders therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide based metabolic disorders therapeutics market size has grown rapidly in recent years. It will grow from $26.03 billion in 2023 to $29.89 billion in 2024 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to increasing prevalence of metabolic disorders, advancements in peptide synthesis technologies, rising healthcare expenditures, a growing aging population, expansion of the biopharmaceutical sector, regulatory approvals for new therapies, and heightened awareness about personalized medicine.

The peptide based metabolic disorders therapeutics market size is expected to see rapid growth in the next few years. It will grow to $52.16 billion in 2028 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to several key factors, including the development of novel peptide analogs, increased research and development investments in metabolic disorders, adoption of precision medicine approaches, expansion in emerging markets, collaborations and partnerships in drug development, advancements in delivery technologies, and a focus on patient-centric therapies. Key trends anticipated in the forecast period include the application of artificial intelligence in drug discovery, the growth of personalized therapies, utilization of CRISPR/Cas9 for genetic therapies, integration of wearable devices for patient monitoring, development of oral peptide formulations, the emergence of digital therapeutics in disease management, and expansion of biobanking for personalized treatments. These trends are expected to significantly shape and propel the peptide-based metabolic disorders therapeutics market in the years to come.

The increasing prevalence of obesity is expected to drive growth in the peptide-based metabolic disorders therapeutic market in the foreseeable future. Obesity, characterized by excessive accumulation of body fat and associated health risks, is becoming more prevalent due to factors such as sedentary lifestyles, unhealthy diets, genetic predisposition, and environmental influences promoting calorie-dense foods and physical inactivity. Peptide-based therapies for metabolic disorders aim to manage conditions such as obesity by utilizing peptides to regulate metabolic functions, improve insulin sensitivity, and control appetite, thereby enhancing patient outcomes and reducing long-term health complications associated with these chronic disorders. For example, a report from the UK's Office for Health Improvement and Disparities noted in May 2023 that 63.8% of adults in England aged 18 and older were estimated to be overweight or obese in the period from 2021 to 2022, up slightly from 63.3% the previous year. Hence, the increasing prevalence of obesity is a key driver for the peptide-based metabolic disorders therapeutic market.

Leading companies in the peptide-based metabolic disorders therapeutic market are focusing on developing innovative treatments, such as biosimilar versions of peptide-based anti-diabetic drugs, to address unmet medical needs and broaden treatment options for patients. Peptide-based anti-diabetic biosimilars replicate existing peptide therapies for diabetes, offering similar efficacy and safety profiles at potentially lower costs through competitive pricing strategies. For instance, Glenmark Pharmaceuticals Ltd., based in India, launched Lirafit in January 2024, a biosimilar of Liraglutide, a popular anti-diabetic medication belonging to the GLP-1 receptor agonist class. These drugs mimic the action of the natural GLP-1 hormone, crucial for regulating blood sugar levels. Clinical trials have demonstrated Lirafit's effectiveness in improving glycemic control, promoting weight loss, and enhancing cardiovascular safety, which are critical benefits in managing diabetes, obesity, and related cardiovascular conditions.

In December 2023, Roche Holding AG, a healthcare company based in Switzerland, completed the acquisition of Carmot Therapeutics Inc. for $2.7 billion. Through this transaction, Roche secures access to Carmot's clinical-stage incretins, including CT-388, a dual GLP-1/GIP receptor agonist currently in Phase 2 trials. This compound holds promise for treating obesity in both diabetic and non-diabetic patients. Carmot Therapeutics Inc., a clinical-stage biotechnology firm, focuses on developing peptide-based therapeutics primarily aimed at metabolic disorders such as diabetes and obesity.

Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide based metabolic disorders therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide-based metabolic disorders therapeutics market consists of sales of semaglutide, dulaglutide, albiglutide, and pramlintide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Based Metabolic Disorders Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide based metabolic disorders therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide based metabolic disorders therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide based metabolic disorders therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Type: Liraglutide; Exenatide; Other Drug Type
  • 2) By Application: Lysosomal Storage Diseases; Diabetes; Obesity; Hypercholesterolemia; Other Applications
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; Merck And Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide Based Metabolic Disorders Therapeutics Market Characteristics

3. Peptide Based Metabolic Disorders Therapeutics Market Trends And Strategies

4. Peptide Based Metabolic Disorders Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Growth

  • 5.1. Global Peptide Based Metabolic Disorders Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Peptide Based Metabolic Disorders Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Peptide Based Metabolic Disorders Therapeutics Market Segmentation

  • 6.1. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Liraglutide
  • Exenatide
  • Other Drug Type
  • 6.2. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lysosomal Storage Diseases
  • Diabetes
  • Obesity
  • Hypercholesterolemia
  • Other Applications
  • 6.3. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Peptide Based Metabolic Disorders Therapeutics Market Regional And Country Analysis

  • 7.1. Global Peptide Based Metabolic Disorders Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Peptide Based Metabolic Disorders Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market

  • 8.1. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Peptide Based Metabolic Disorders Therapeutics Market

  • 9.1. China Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 9.2. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Peptide Based Metabolic Disorders Therapeutics Market

  • 10.1. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Peptide Based Metabolic Disorders Therapeutics Market

  • 11.1. Japan Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 11.2. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Peptide Based Metabolic Disorders Therapeutics Market

  • 12.1. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Peptide Based Metabolic Disorders Therapeutics Market

  • 13.1. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Peptide Based Metabolic Disorders Therapeutics Market

  • 14.1. South Korea Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 14.2. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Peptide Based Metabolic Disorders Therapeutics Market

  • 15.1. Western Europe Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 15.2. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Peptide Based Metabolic Disorders Therapeutics Market

  • 16.1. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Peptide Based Metabolic Disorders Therapeutics Market

  • 17.1. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Peptide Based Metabolic Disorders Therapeutics Market

  • 18.1. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Peptide Based Metabolic Disorders Therapeutics Market

  • 19.1. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Peptide Based Metabolic Disorders Therapeutics Market

  • 20.1. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market

  • 21.1. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 21.2. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Peptide Based Metabolic Disorders Therapeutics Market

  • 22.1. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Peptide Based Metabolic Disorders Therapeutics Market

  • 23.1. North America Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 23.2. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Peptide Based Metabolic Disorders Therapeutics Market

  • 24.1. USA Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 24.2. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Peptide Based Metabolic Disorders Therapeutics Market

  • 25.1. Canada Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 25.2. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Peptide Based Metabolic Disorders Therapeutics Market

  • 26.1. South America Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 26.2. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Peptide Based Metabolic Disorders Therapeutics Market

  • 27.1. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Peptide Based Metabolic Disorders Therapeutics Market

  • 28.1. Middle East Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 28.2. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Peptide Based Metabolic Disorders Therapeutics Market

  • 29.1. Africa Peptide Based Metabolic Disorders Therapeutics Market Overview
  • 29.2. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Peptide Based Metabolic Disorders Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Peptide Based Metabolic Disorders Therapeutics Market Competitive Landscape
  • 30.2. Peptide Based Metabolic Disorders Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson And Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Roche Holding AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck And Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Peptide Based Metabolic Disorders Therapeutics Market Other Major And Innovative Companies

  • 31.1. Sanofi SA
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. AstraZeneca PLC
  • 31.4. Novartis AG
  • 31.5. Takeda Pharmaceutical Company Limited
  • 31.6. GlaxoSmithKline plc
  • 31.7. Boehringer Ingelheim International GmbH
  • 31.8. Eli Lilly Company
  • 31.9. Amgen Inc.
  • 31.10. Gilead Sciences Inc.
  • 31.11. Novo Nordisk A/S
  • 31.12. Teva Pharmaceutical Industries Ltd.
  • 31.13. Regeneron Pharmaceuticals Inc.
  • 31.14. Biogen Inc.
  • 31.15. Vertex Pharmaceuticals Incorporated

32. Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Benchmarking

33. Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Peptide Based Metabolic Disorders Therapeutics Market

35. Peptide Based Metabolic Disorders Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Peptide Based Metabolic Disorders Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Peptide Based Metabolic Disorders Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Peptide Based Metabolic Disorders Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer